

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: True Leaf Medicine International Ltd. (the "Issuer").

Trading Symbol: MJ

Number of Outstanding Listed Securities: 95,369,059 common shares (plus 11,347,382 common shares reserved for issuance in the form of 5,440,237 warrants and 5,907,145 options)

Date: April 5, 2018

Report on Business

- 1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

During the past month, the Issuer generally continued to market its pet products and to develop its pet products line.

On March 2, 2018 the Issuer announced that it started construction on its True Leaf Campus cannabis production facility in Lumby, British Columbia. Phase one of the project is planned to include a 16,000 square foot cannabis cultivation facility, and an additional 9,000 square feet laboratory services, whole-plant extraction, and production of therapeutic cannabis products. Together, the facilities will be known as True Leaf Campus, a hub for the development of the Issuer's medical cannabis products.

On March 19, 2018 the Issuer announced the formation of its cannabis cultivation team with the addition of team members Stephan Schroeder, Chief Cannabis Industry Advisor, and Christian Zofchak, Director of Horticulture Operations. The cannabis cultivation team members are Canadian leaders in selective cannabis plant development. Their objective is to identify the best cannabis plant genetics worldwide, and, as part of the Issuer's proprietary intellectual property, develop unique strains capable of producing the active ingredients needed to develop a highly-effective medicinal product line to address neurological, musculoskeletal, gynaecological, and gastrointestinal conditions.

On March 27, 2018 the Issuer announced the formation of its Medical Advisory Board under the direction of its Chief Scientific Officer, Dr. Christopher Spooner. Dr. Spooner will be joined by Dr. Caroline MacCallum and Dr. Zeid Mohamedali. This team of leading British Columbian medical practitioners are committed to advancing integrative healthcare with cannabis.

2. **Provide a general overview and discussion of the activities of management.**

Please see Item 1 above.

3. **Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.**

None, except in the ordinary course of business.

4. **Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.**

None.

5. **Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.**

None.

6. **Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.**

None.

7. **Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.**

None.

8. **Describe the acquisition of new customers or loss of customers.**

None, except in the ordinary course of business.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None, except in the ordinary course of business.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Please see Item 1 above.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
Common Shares	100,000	These shares were issued on March 7, 2018 at a price of \$0.395 per share pursuant to option exercises.	\$39,500 for general working capital.

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

None.

17. **Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.**

None.

[Certificate on Next Page]

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated April 5, 2018.

Darcy Bomford
Name of Director or Senior Officer

"Darcy Bomford"
Signature

Chief Executive Officer
Official Capacity

Issuer Details Name of Issuer	For Month End	Date of Report YY/MM/DD
True Leaf Medicine International Ltd.	March 2018	18/04/05
Issuer Address		
100 Kalamalka Lake Road, Unit 32		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Vernon, British Columbia V1T 9G1	N/A	778.475.5323
Contact Name	Contact Position	Contact Telephone No.
Darcy Bomford	President, CEO, and Director	778.475.5323
Contact Email Address	Web Site Address	
Darcy@trueleaf.com	www.trueleaf.com	